TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A video recorded after the American Academy of Dermatology meeting highlighted several approaches under study or in use for chronic urticaria, including BTK inhibition, c-KIT targeting and IL-4 receptor blockade. The discussion points to a broader treatment landscape, but the source does not provide full trial results or establish how the approaches compare.
A discussion following the American Academy of Dermatology meeting highlighted a widening range of treatment approaches for chronic spontaneous urticaria (CSU), including BTK inhibition, c-KIT targeting and IL-4 receptor blockade. Brian Kim of the Icahn School of Medicine at Mount Sinai described remibrutinib, dupilumab and investigational c-KIT strategies as notable developments, while the available report does not provide detailed trial data to compare their benefits or risks.
Kim said remibrutinib, marketed as Rhapsido, was a major topic at the meeting. He described it as a recently approved BTK inhibitor for CSU and said Phase III results had also been reported in three forms of chronic inducible urticaria (CIndU): dermatographism, cold urticaria and cholinergic urticaria. The report does not include the results’ numerical measures, study designs or safety findings.
Kim also discussed dupilumab (Dupixent), which targets the IL-4 receptor and is used across multiple type 2 inflammatory disease indications, and barzolvolimab, a c-KIT inhibitor. He said barzolvolimab may both inhibit and deplete mast cells. That description is Kim’s characterization; the source does not give clinical outcome data establishing the extent or effects of mast-cell depletion.
Kim disclosed that he co-founded Alys Pharma, which is developing a c-KIT inhibitor using a bispecific strategy intended to block c-KIT on mast cells. That potential approach remains distinct from evidence of an established treatment benefit. The source offers no trial results for the company’s candidate.
More Targets, More Treatment Questions
The developments matter because CSU and CIndU are being discussed alongside several different biological targets, rather than a single treatment pathway. BTK, c-KIT and IL-4 receptor approaches could give clinicians and researchers more avenues to investigate for people whose symptoms are not adequately controlled with existing options. The meeting discussion also points to interest in whether therapies may apply across different forms of inducible urticaria.
However, a wider pipeline does not by itself show that patients will have better outcomes. The report does not compare treatments head to head, describe how long benefits last, or give details about adverse effects, eligibility or access. Those questions will require complete trial results and regulatory information. For now, the development is a report of expanding research and treatment options, not evidence that one approach is best for a particular patient.
Products Worth Considering
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale
Levoit Core 300S-P Smart Wi-Fi Air Purifier
As an affiliate, we earn on qualifying purchases.
From CSU to Inducible Hives
Chronic spontaneous urticaria refers to recurring hives without a consistent identifiable external trigger. Chronic inducible urticaria involves symptoms associated with triggers such as pressure or friction, cold, or rises in body temperature. The conditions can affect daily life, but the source report does not quantify their prevalence or describe individual patient experiences.
The AAD session discussed both CSU and CIndU. Kim said it was only the meeting’s second session focused on CSU, following an earlier one. His comments were recorded after the April meeting in Denver and published by MedPage Today on October 8, 2026. The report is a short video transcript, rather than a detailed presentation of trial publications.
“a recently approved drug, a BTK inhibitor for chronic spontaneous urticaria”
— Brian Kim
Trial Evidence Still Needed
The source provides no numerical Phase III results for remibrutinib in CIndU, no detailed efficacy or safety data for the therapies discussed, and no direct comparisons among them. It also does not specify the development stage or expected trial milestones for the Alys Pharma candidate. Kim’s comments about c-KIT inhibition and mast-cell depletion should be understood as an expert’s account of the approach, not as a complete report of clinical evidence.
It remains unclear from this report how regulators or clinical guidelines may treat the different candidates, which patient groups might benefit, and when additional data will be available. The meeting discussion alone cannot answer those questions.
Watch for Full Trial Results
The next useful developments will be fuller reports of the Phase III CIndU studies and further published or presented results on CSU treatments. Those materials can clarify study populations, measured outcomes, duration of benefit and side effects. Updates on the c-KIT programs will also be needed to show whether the proposed targeting strategies advance through clinical testing.
Until then, the meeting report establishes that researchers are pursuing several targets, but not how the approaches perform relative to one another. Treatment decisions remain individual and should be discussed with a qualified health professional.
Key Questions
What treatments were discussed at the AAD meeting?
The report discusses remibrutinib, a BTK inhibitor; dupilumab, which targets the IL-4 receptor; and c-KIT approaches including barzolvolimab and a bispecific candidate being developed by Alys Pharma.
What did Kim say about remibrutinib?
Kim described remibrutinib as a recently approved treatment for CSU and said Phase III results had been reported in dermatographism, cold urticaria and cholinergic urticaria. The article does not provide the study results in detail.
Are the c-KIT treatments proven to work?
The source describes c-KIT strategies and Kim’s view that barzolvolimab may inhibit and deplete mast cells, but it does not provide enough clinical data to establish their effectiveness or compare them with other treatments.
What is the difference between CSU and CIndU?
CSU involves recurring hives without a consistent external trigger. CIndU refers to hives associated with particular triggers, including friction or pressure, cold, or increased body temperature.
When will more information be available?
The report gives no dates for upcoming results or regulatory milestones. Full trial publications and later meeting presentations may provide more detail on benefits, risks and which patients were studied.
Source: rss
